Abstract
A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
| Original language | English |
|---|---|
| Pages (from-to) | 1072-1074 |
| Number of pages | 3 |
| Journal | Neurology |
| Volume | 52 |
| Issue number | 5 |
| State | Published - Mar 23 1999 |
Fingerprint
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
A safety and pharmacokinetic study of intravenous natalizumab in patients with MS. / Sheremata, William; Vollmer, T. L.; Stone, L. A.; Willmer-Hulme, A. J.; Koller, M.
In: Neurology, Vol. 52, No. 5, 23.03.1999, p. 1072-1074.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A safety and pharmacokinetic study of intravenous natalizumab in patients with MS
AU - Sheremata, William
AU - Vollmer, T. L.
AU - Stone, L. A.
AU - Willmer-Hulme, A. J.
AU - Koller, M.
PY - 1999/3/23
Y1 - 1999/3/23
N2 - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
AB - A phase 1, randomized, placebo-controlled, five-level dose escalation safety and tolerability and pharmacokinetic study of a single IV dose of natalizumab was performed. Doses of 0.03 to 3.0 mg/kg natalizumab or placebo were studied in 28 stable relapsing-remitting or secondary-progressive MS. All doses were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.
UR - http://www.scopus.com/inward/record.url?scp=0033596831&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033596831&partnerID=8YFLogxK
M3 - Article
C2 - 10102433
AN - SCOPUS:0033596831
VL - 52
SP - 1072
EP - 1074
JO - Neurology
JF - Neurology
SN - 0028-3878
IS - 5
ER -